icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Safety and Efficacy of Treatment with Sofosbuvir + GS-5816 ± Ribavirin for 8 or 12 Weeks in Treatment-Na´ve Patients with Genotype 1-6 HCV Infection
 
 
  Reported by Jules Levin
AASLD Boston Nov 8-11 2014
 
Tram T. Tran1, Timothy R. Morgan2 , Paul J. Thuluvath3, Kyle Etzkorn4, Federico Hinestrosa5, Myron Tong6, John McNally7, Diana M. Brainard7, Lingling Han7, Brian Doehle7, Erik Mogalian7, John G. McHutchison7, Raymond T. Chung8, Gregory T. Everson9 1Cedars-Sinai Medical Center, Los Angeles, CA; 2VA Long Beach, Long Beach, CA; 3Mercy Medical Center, Baltimore, MD; 4Borland-Groover Clinic, Jacksonville, FL; 5Orlando Immunology Center, Orlando, FL; 6Huntington Medical Research Institutes, Pasadena, CA; 7Gilead Sciences, Inc., Foster City, CA; 8Massachusetts General Hospital, Boston, MA; 9University of Colorado Denver, Aurora, CO

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif

AASLD12.gif

AASLD13.gif